您的购物车当前为空
KML29 是一种口服具有活性的、高度选择性的不可逆 MAGL 抑制剂,其对小鼠、大鼠和人的 IC50值分别为15 nM、43 nM 和 5.9 nM。它对 FAAH 在内的其他中心和外周丝氨酸水解酶的交叉反应极小。


为众多的药物研发团队赋能,
让新药发现更简单!
KML29 是一种口服具有活性的、高度选择性的不可逆 MAGL 抑制剂,其对小鼠、大鼠和人的 IC50值分别为15 nM、43 nM 和 5.9 nM。它对 FAAH 在内的其他中心和外周丝氨酸水解酶的交叉反应极小。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 117 | In stock | |
| 5 mg | ¥ 263 | In stock | |
| 10 mg | ¥ 440 | In stock | |
| 25 mg | ¥ 953 | In stock | |
| 50 mg | ¥ 1,530 | In stock | |
| 100 mg | ¥ 2,470 | 待询 | |
| 200 mg | ¥ 3,470 | 待询 | |
| 1 mL x 10 mM (in DMSO) | ¥ 317 | In stock |
KML29 相关产品
| 产品描述 | KML29 is highly selective and effective monoacylglycerol lipase (MAGL) inhibitor. It has effective inhibition of human/mouse/rat MAGL (IC50: 5.9/15/43 nM). It has not inhibitory for FAAH (IC50 > 50 μM). It also effectively and selectively blocks hydrolysis of 2-arachidonoylglycerol (2-AG) in mice (IC50: 2.5 nM, 2-AG; >50 μM, AEA). |
| 靶点活性 | MAGL (human):5.9 nM, MAGL (rat):43 nM, MAGL (mouse):15 nM, 2-AG:2.5 nM, AEA:>50 μM |
| 体内活性 | DprE1-IN-2 has efficacy in a rodent model of tuberculosis. |
| 分子量 | 549.42 |
| 分子式 | C24H21F6NO7 |
| CAS No. | 1380424-42-9 |
| Smiles | OC(C1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)(c1ccc2OCOc2c1)c1ccc2OCOc2c1 |
| 密度 | 1.511 g/cm3 (Predicted) |
| 颜色 | White |
| 物理性状 | Solid |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 50 mg/mL (91.01 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.64 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
评论内容